Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne
Sagimet Biosciences Inc. (SGMT)
Company Research
Source: PR Newswire
-Phase III trial enrolled a total of 480 patients with moderate to severe acne-Topline results expected in the second quarter 2025HANGZHOU, China, Nov. 12, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces completion of enrollment of 480 patients for Phase III clinical trial of ASC40 (denifanstat) once-daily oral tablet for treatment of moderate to severe acne. The first patient was enrolled on January 24, 2024.This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40 once-daily oral tablet for the treatment of moderate to severe acne vulgaris. 480 patients with moderate to severe acne vulgaris were enrolled and randomized into one active treatment arm and one placebo control arm at the ratio of 1:1 to receive 50 mg ASC40 oral tablet once daily or matching placebo for 12 weeks. Topline results are expected in the second quarter 2025.The primary effic
Show less
Read more
Impact Snapshot
Event Time:
SGMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SGMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SGMT alerts
High impacting Sagimet Biosciences Inc. news events
Weekly update
A roundup of the hottest topics
SGMT
News
- Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024 [Yahoo! Finance]Yahoo! Finance
- Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024GlobeNewswire
- Sagimet Biosciences Inc. (NASDAQ: SGMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.MarketBeat
- Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates [Yahoo! Finance]Yahoo! Finance
- Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate UpdatesGlobeNewswire
SGMT
Earnings
- 11/14/24 - Beat
SGMT
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- SGMT's page on the SEC website